Over 96 million adults on the brink of developing diabetes. 1 in 3 people in the USA have diabetes. A healthtech innovator partnered with Zemoso to productize a solution that enables prevention using machine learning (ML) and artificial intelligence (AI).
Diabetes, if diagnosed early, can be prevented or delayed with individualized care programs, better treatments, and regular screening. However, conventional diabetes solutions, like continuous blood glucose monitoring (CGM) devices for diabetes are reactive, primarily built for managing diabetes, leaving a gap in prevention efforts. Our client identified this missed opportunity and developed a proactive solution that can predict the onset of diabetes up to 5 years in advance. By alerting individuals before symptoms even appear, the solution empowers people to make lifestyle changes and healthcare professionals to allocate appropriate resources and care to high-risk patients.
The healthtech company partnered with Zemoso for our ability to build nuanced AI-ML models, and take it to development with mature engineering and design practices. At every step, we evaluated the AI-ML model on accuracy, and its ability to be incorporated into the product. We helped our customer to navigate product innovation, and turn a good idea into a great product through:
Our product, design, and engineering pods actively collaborated with stakeholders to launch the Minimum Viable Product (MVP) version. Our partnership with this healthtech innovator was split into two phases:
The initial phase of our partnership was focused on validating the idea and creating a concrete proof of concept to demonstrate its feasibility.
Customized Design Sprint: We kicked off the partnership with a customized design sprint inspired by the Google Ventures Design Sprint to dig into the challenges faced by patients, healthcare providers, and insurance companies.
Diverge and Converge: Applying the double-diamond approach and deep research, we created space for brainstorming and prioritization — converging to focus on primary and immediate pain points.
Golden Path: We used the Jobs-to-be-Done (JTBD) framework to map out the golden path, followed by building, testing, and iterating the proof of concept via a prototype with pilot customers.
We had some early wins with positive response from early adopters with the prototype. We then put the ML algorithm into production and created a solution that could predict the onset of diabetes in patients with near-perfect accuracy, like no other solution in the market. The learning and improving the accuracy of the model was of course a priority.
Leveraging mature engineering practices, this is how we partnered with our customer to expand product capabilities:
Data Sourcing: We aggregated data from OpenEHR and a partner hospital. Of course all the data was obfuscated to maintain compliance with HIPAA standards of privacy. We cleaned it up and filled in the gaps in the data using imputation techniques.
Feature Selection and Engineering: We worked with the client to identify high-impact features from a wide range of potential predictors and built them for improved performance.
Algorithm Development: Our engineers built a fast-learning, self-improving algorithm utilizing the Accelerated Failure Time (AFT) survival regression model due to its suitability for modeling individual time-to-event data. This choice proved instrumental in achieving 85% accuracy in predicting the onset of diabetes.
Multi-modal Data Fusion: We utilized multiple modes of biometric and demographic data from various sources, including hospital visits and social history, followed by streamlining, processing, and feeding data into the model to facilitate continuous training.
Continuous Improvement: With each new iteration and implementation, we ensured that the algorithm continued to learn and improve its predictions, resulting in a continuously evolving and highly accurate solution.
Robust CI/CD pipelines: A Continuous Integration/Continuous Deployment (CI/CD) pipeline was deployed to shorten feedback loops and consistently meet product engineering milestones.
Scalability: We designed the solution to be easily scalable by streamlining data ingestion and processing, ensuring that it can handle increasing data volumes without compromising performance.
Zemoso has always been at the forefront of AI innovation across industries as we enable innovators to solve critical problems by leveraging the power of data, AI, and ML.
If you have an idea with the potential to make a big impact, but it's been waiting for the right moment, let's talk. We can bring it to life with a proof of concept in 2 weeks. We have expertise in delivering realistic prototypes for AI/ML, and Generative AI use cases for startups and enterprises.
P.S. We have strict Non-disclosure agreements (NDAs) with many of our clients. The data, insights, and capabilities discussed in this case study have been anonymized to protect our client’s identity and don’t include any proprietary information.
©2023 Zemoso Technologies. All rights reserved.